About Apollo Endo
Apollo Endo is a company based in Austin (United States) founded in 2005 was acquired by Boston Scientific in November 2022. Apollo Endo has raised $80.36 million across 13 funding rounds from investors including Boston Scientific, UTMB Health and PTV Healthcare Capital. The company has 132 employees as of December 31, 2022. Apollo Endo offers products and services including Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera. Apollo Endo operates in a competitive market with competitors including Allurion, USGI Medical, ReShape, Cyted and Vibrynt, among others.
- Headquarter Austin, United States
- Employees 132 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apollo Endosurgery, Inc.
-
Annual Revenue
$76.86 M (USD)22as on Dec 31, 2022
-
Net Profit
-$39.84 M (USD)-61as on Dec 31, 2022
-
EBITDA
-$31.42 M (USD)-64as on Dec 31, 2022
-
Total Equity Funding
$80.36 M (USD)
in 13 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jul 20, 2020
-
Investors
Boston Scientific
& 8 more
-
Employee Count
132
as on Dec 31, 2022
-
Acquired by
Boston Scientific
(Nov 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Apollo Endo
Apollo Endo offers a comprehensive portfolio of products and services, including Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera.
Reduces stomach size endoscopically to facilitate weight loss.
Adjusts previous gastric bypass for effective weight management.
Occupies stomach space to suppress appetite and aid weight loss.
People of Apollo Endo
Unlock access to complete
Unlock access to complete
Funding Insights of Apollo Endo
Apollo Endo has successfully raised a total of $80.36M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Apollo Endo
Apollo Endo has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, UTMB Health and PTV Healthcare Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in expansion & late stage start-ups in the US
|
Locked | Locked | Locked |
Investor details for Apollo Endo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apollo Endo
Investment portfolio details for Apollo Endo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Apollo Endo
Detailed financials for Apollo Endo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apollo Endo Comparisons
Peer comparison for Apollo Endo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Apollo Endo
Apollo Endo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Allurion, USGI Medical, ReShape, Cyted and Vibrynt, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
|
|
| Locked | Locked | Locked |
Incisionless operating platform for weight loss surgery
|
|
| Locked | Locked | Locked |
A dual intra-gastric balloon system is provided for weight loss.
|
|
| Locked | Locked | Locked |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| Locked | Locked | Locked |
Provides durable coat hooks and storage solutions for home use.
|
Detailed competitors of Apollo Endo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apollo Endo
Complete news archive for Apollo Endo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apollo Endo
Apollo Endo was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Apollo Endo is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Chas McKhann is the current CEO of Apollo Endo.
Apollo Endo is a funded company, having raised a total of $80.36M across 13 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Apollo Endo is 132.
Annual revenue of Apollo Endo is $76.86M as on Dec 31, 2022.
Apollo Endo was founded in 2005 in Austin, United States, focusing on medical devices within the gastrointestinal sector. Therapeutic solutions for obesity and related disorders are developed, including the Orbera intragastric balloon for portion control and weight management. Additional products encompass the OverStitch Endoscopic Suturing System for advanced endoscopic procedures and the LAP-BAND adjustable gastric banding system. Operations emphasize endoscopic innovations to support clinical applications.
Apollo Endo's top competitors include Allurion, ReShape and GT Metabolic Solutions.
Apollo Endo offers Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera.
Apollo Endo has 9 investors. Key investors include Boston Scientific, UTMB Health, PTV Healthcare Capital, Athyrium Capital Management, and Remeditex.